Specific Killing of Ph+ Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/abl Small Hairpin RNA

Oligonucleotides

Volumn 13, Issue 5, 2003, Pages 401-409

  Li, Ming Jie ^a   McMahon, Ross ^a   Snyder, David S ^a   Yee, Jiing Kuan ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; LENTIVIRUS VECTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL KILLING; CELL PROLIFERATION; CELL STRAIN K 562; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

BASE SEQUENCE; CELL DIVISION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC VECTORS; HUMANS; K562 CELLS; LENTIVIRUS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PHILADELPHIA CHROMOSOME; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 1642564293     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/154545703322617087     Document Type: Article

References (61)

1. ARNOLD, K. (2001). After 30 years of laboratory work, a quick approval for STI571. J. Natl. Cancer Inst. 93, 972.
2. + progenitor cell-derived macrophages. Mol. Ther. 8, 62-71.
3. BARNETT, M.J., and EAVES, C.J. (2002). Chronic myeloid leukemia. In: Leukemia. E.S. Henderson, T.A. Lister, and M.F. Greaves, eds, (Saunders, Philadelphia), pp. 583-600.
4. BARTRAM, C.R., DE KLEIN, A., HAGEMEIJER, A., VAN AGTHOVEN, T., GEURTS VAN KESSEL, A., BOOTSMA, D., GROSVELD, G., FERGUSON-SMITH, M.A., DAVIES, T., STONE, M., et al. (1983). Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia, Nature 306, 277-280.
5. BEELEN, D.W., and SCHAEFER, U.W. (2002). Allogeneic stem cell transplants in chronic myeloid leukemia. Ann. Hematol. 81 (Suppl. 2), S45-46.
6. BOHULA, E.A., SALISBURY, A.J., SOHAIL, M., PLAYFORD, M.P., RIEDEMANN, J., SOUTHERN, E.M., and MACAULAY, V.M. (2003). The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem. 278, 15991-15997.
7. BRUMMELKAMP, T.R., BERNARDS, R., and AGAMI, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553.
8. CLARK, R.E. (2000). Antisense therapeutics in chronic myeloid leukemia: The promise, the progress and the problems. Leukemia 14, 347-355.
9. COHEN, M.H., MOSES, M.L., and PAZDYR, R. (2002). Gleevec for the treatment of chronic myelogenous leukemia: U.S. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist 7, 390-392.
10. CORSETTI, M.T., LERMA, E., DEJANA, A., CAVALIERE, M., FIGARI, O., VASSALLO, F., ABATE, M., LUCHETTI, S., PIAGGIO, G., PARODI, C., PIRA, G.L., MANCA, F., and CARELLA, A.M. (2000). Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft. Exp. Hematol. 28, 104-111.
11. DE FABRITIIS, P., PETTI, M.C., MONTEFUSCO, E., DE PROPRIS, M.S., SALA, R., BELLUCCI, R., MANCINI, M., LISCI, A., BONETTO, F., GEISER, T., CALABRETTA, B., and MANDELLI, F. (1998). BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 91, 3156-3162.
12. DOBROVIC, A., MORLEY, A.A., SESHADRI, R., and JANUSZEWICZ, E.H. (1991). Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: Clinical features and course of M-bcr negative and M-bcr positive CML. Leukemia 5, 187-190.
13. DOHJIMA, T., SOOK LEE, N., LI, H., OHNO, T., and ROSSI, J.J. (2003). Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7, 811-816.
14. DRUKER, B.J., TAMURA, S., BUCHDUNGER, E., OHNO, S., SEGAL, G.M., FANNING, S., ZIMMERMANN, J., and LYDON, N.B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
15. EGERER, G., GOLDSCHMIDT, H., ZOZ, M., and HO, A.D. (2003). Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemia. Leuk. Lymphoma 44, 9-14.
16. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
17. ESPEROU, H., BOIRON, J.M., CAYUELA, J.M., BLANCHET, O., KUENTZ, M., JOUET, J.P., MILPIED, N., CAHN, J.Y., FAUCHER, C., BOURHIS, J.H., MICHALLET, M., TANGUY, M.L., VERNANT, J.P., GABERT, J., BORDIGONI, P., IFRAH, N., BARUCHEL, A., and DOMBRET, H. (2003). A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 31, 909-918.
18. FIRE, A., XU, S., MONTGOMERY, M.K., KOSTAS, S.A., DRIVER, S.E., and MELLO, C.C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
19. HEIDENREICH, O., KRAUTER, J., RIEHLE, H., HADWIGER, P., JOHN, M., HEIL, G., VORNLOCHER, H.P., and NORDHEIM, A. (2003). AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101, 3157-3163.
20. HEISTERKAMP, N., JENSTER, G., TEN HOEVE, J., ZOVICH, D., PATTENGALE, P.K., and GROFFEN, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature 344, 251-253.
21. HEISTERKAMP, N., STEPHENSON, J.R., GROFFEN, J., HANSEN, P.F., DE KLEIN, A., BARTRAM, C.R., and GROSVELD, G. (1983). Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306, 239-242.
22. HOCHHAUS, A., KREIL, S., CORBIN, A.S., LA ROSEE, P., MULLER, M.C., LAHAYE, T., HANFSTEIN, B., SCHOCH, C., CROSS, N.C., BERGER, U., GSCHAIDMEIER, H., DRUKER, B.J., and HEHLMANN, R. (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2196.
23. HONMA, Y., MATSUO, Y., HAYASHI, Y., and OMURA, S. (1995). Treatment of Philadelphia chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor. Int. J. Cancer 60, 685-688.
24. JACQUE, J.M., TRIQUES, K., and STEVENSON, M. (2002). Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438.
25. JAMES, H., MILLS, K., and GIBSON, I. (1996). Investigating and improving the specificity of ribozymes directed against the bcr-bcl translocation. Leukemia 10, 1054-1064.
26. KANTARJIAN, H.M., and TALPAZ, M. (2001). Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol. 28, 9-18.
27. KRETSCHMER-KAZEMI FAR, R., and SCZAKIEL, G. (2003). The activity of siRNA in mammalian cells is related to structural target accessibility: A comparison with antisense oligonucleotides. Nucleic Acids Res. 31, 4417-4424.
28. LEE, N.S., DOHJIMA, T., BAUER, G., LI, H., LI, M.J., EHSANI, A., SALVATERRA, P., and ROSSI, J. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500-505.
29. LI, M.J., BAUER, G., MICHIENZI. A., YEE, J.K., LEE, N.S., KIM, J., LI, S., CASTANOTTO, D., ZAIA, J., and ROSSI, J.J. (2003). Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. 8, 196-206.
30. LUGO, T.G., PENDERGAST, A.M., MULLER, A.J., and WITTE, O.N. (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082.
31. MAKI, G., TAM, Y.K., BERKAHN, L., and KLINGEMANN, H.G. (2003). Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia. Bone Marrow Transplant. 31, 1119-1125.
32. MAURER, J., JANSSEN, J.W., THIEL, E., VAN DENDEREN, J., LUDWIG, W.D., AYDEMIR, U., HEINZE, B., FONATSCH, C., HARBOTT, J., REITER, A., et al. (1991). Detection of chimeric bcr-abl genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 337, 1055-1058.
33. MAURO, M.J., O'DWYER, M.E., and DRUKER, B.J. (2001). ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy. Cancer Chemother. Pharmacol. 48(Suppl 1), S77-78.
34. McLAUGHLIN, J., CHIANESE, E., and WITTE, O.N. (1987). In vitro transformation of immature hematopoietic cells by the P210 bcr/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84, 6558-6562.
35. MENDOZA-MALDONADO, R., ZENTILIN, L., FANIN, R., and GIACCA, M. (2002). Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. Cancer Gene Ther. 9, 71-86.
36. NOWELL, P.C., and HUNGERFORD, D.A. (1960). Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst. 25, 85-109.
37. NOWELL, P.C., and HUNGERFORD, D.A. (1961). Chromosome studies in human leukemia: Chronic granulocytic leukemia. J. Natl. Cancer Inst. 27, 1013-1035.
38. OLIVEIRA, D.M., and GOODELL, M.A. (2003). Transient RNA interference in hematopoietic progenitors with functional consequences. Genesis 36, 203-208.
39. PATERSON, S.C., SMITH, K.D., HOLYOAKE, T.L., and JORGENSEN, H.G. (2003). Is there a cloud in the silver lining for imatinib? Br. J. Cancer 88, 983-987.
40. PEGGS, K., and MACKINNON, S. (2003). Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia. N. Engl. J. Med. 348, 1048-1050.
41. + cells from chronic myeloid leukemia. Leuk. Lymphoma 36, 569-578.
42. Radford, I.R. (2002). Imatinib. Novartis. Curr. Opin. Invest. Drugs 3, 492-499.
43. RODRIGUES, C.A., FERMINO, F.A., VASCONCELOS, Y., and DE OLIVEIRA, J.S. (2003). Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CML. Bone Marrow Transplant. 32, 333-335.
44. ROWLEY, J.D. (1973). A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [Letter]. Nature 243, 290-293.
45. SACHA, T., HOCHHAUS, A., HANFSTEIN, B., MULLER, M.C., RUDZKI, Z., CZOPEK, J., WOLSKA-SMOLEN, T., CZEKALSKA, S., SALAMANCHUK, Z., JAKOBCZYK, M., and SKOTNICKI, A.B. (2003). ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patients who progress to myeloid blast crisis. Leuk. Res. 27, 1163-1166.
46. SANDBERG, A.A. (1980). Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CML. Cancer 46, 2221-2226.
47. SCHERR, M., BATTMER, K., WINKLER, T., HEIDENREICH, O., GANSER, A., and EDER, M. (2003). Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101, 1566-1569.
48. SHARP, P.A. (2001). RNA interference-2001. Genes Dev. 15, 485-490.
49. SNYDER, D.S., WU, Y., McMAHON, R., YU, L., ROSSI, J.J., and FORMAN, S.J. (1997). Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol. Blood Marrow Transplant. 3, 179-186.
50. SNYDER, D.S., WU, Y., WANG, J.L., ROSSI, J.J., SWIDERSKI, P., KAPLAN, B.E., and FORMAN, S.J. (1993). Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82, 600-605.
51. THAMBI, P., and SAUSVILLE, E.A. (2002). STI571 (imatinib mesylate): The tale of a targeted therapy. Anticancer Drugs 13, 111-114.
52. VEY, N., BALATZENTKO, G., LAFAGE, M., SAINTY, D., BOUABDALLAH, R., CHABANNON, C., BLAISE, D., GASTAUT, J.A., and GABERT, J. (2001). Survey of early disapearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia. Leuk. Lymphoma. 42, 945-952.
53. VICKERS, T.A., KOO, S., BENNETT, C.F., CROOKE, S.T., DEAN, N.M., and BAKER, B.F. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108-7118.
54. VON BUBNOFF, N., PESCHEL, C., and DUYSTER, J. (2003). Resistance of Philadelphia chromosome-positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back. Leukemia 17, 829-838.
55. WESTBROOK, C.A., HOOBERMAN, A.L., SPINO, C., DODGE, R.K., LARSON, R.A., DAVEY, F., WURSTERHILL, D.H., SOBOL, R.E., SCHIFFER, C., and BLOOMFIELD, C.D. (1992). Clinical significance of the bcr-abl fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762). Blood 80, 2983-2990.
56. WILDA, M., FUCHS, U., WOSSMANN, W., and BORKHARDT, A. (2002). Killing of leukemic cells with a bcr/abl fusion gene by RNA interference (RNAi). Oncogene 21, 5716-5724.
57. WOHLBOLD, L., VAN DER KUIP, H., MIETHING, C., VORNLOCHER, H.P., KNABBE, C., DIYSTER, J., and AULITZKY, W.E. (2003). Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102, 2236-2239.
58. WU, Y., YU, L., McMAHON, R., ROSSI, J.J., FORMAN, S.J., and SNYDER, D.S. (1999). Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene Ther. 10, 2847-2857.
59. YAM, P.Y., LI, S., WU, J., HU, J., ZAIA, J.A., and YEE, J.K. (2002). Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol. Ther. 5, 479-484.
60. YANG, G., THOMPSON, J.A., FANG, B., and LIU, J. (2003). Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene 22, 5694-5701.
61. ZONDER, J.A., and SCHIFFER, C.A. (2003). Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate. Curr. Hematol. Rep. 2, 57-64.